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Abstract
Background: Cyclin D1 is integral for the G1 to S phase of the cell cycle as it regulates cellular
proliferation. A polymorphism in cyclin D1, 870 G>A, causes overexpression and supports
uncontrollable cellular growth. This polymorphism has been associated with an increased risk of
developing many cancers, including endometrial cancer.
Methods: The 870 G>A polymorphisms (rs605965) in the cyclin D1 gene was genotyped in an
Australian endometrial cancer case-control population including 191 cases and 291 controls using
real-time PCR analysis. Genotype analysis was performed using chi-squared (χ2) statistics and odds
ratios were calculated using unconditional logistic regression, adjusting for potential endometrial
cancer risk factors.
Results: Women homozygous for the variant cyclin D1 870 AA genotype showed a trend for an
increased risk of developing endometrial cancer compared to those with the wild-type GG
genotype, however this result was not statistically significant (OR 1.692 95% CI (0.939–3.049), p =
0.080). Moreover, the 870 G>A polymorphism was significantly associated with family history of
colorectal cancer. Endometrial cancer patients with the homozygous variant AA genotype had a
higher frequency of family members with colorectal cancer in comparison to endometrial cancer
patients with the GG and combination of GG and GA genotypes (GG versus AA; OR 2.951, 95%
CI (1.026–8.491), p = 0.045, and GG+GA versus AA; OR 2.265, 95% CI (1.048–4.894), p = 0.038,
respectively).
Conclusion: These results suggest that the cyclin D1 870 G>A polymorphism is possibly involved
in the development of endometrial cancer. A more complex relationship was observed between
this polymorphism and familial colorectal cancer.
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Background
Cyclin D1 (CCND1) is a key protein in the regulation of
the cell cycle at the G1 to S phase transition, and is essen-
tial for regulation of proliferation, differentiation and
transcriptional control [1]. Overexpression of cyclin D1
induces excessive cellular proliferation and is a feature of
a number of cancers, including endometrial and colorec-
tal cancer [2-6]. Specifically for endometrial cancer,
numerous studies have reported increased cellular prolif-
eration co-existing with progressive derailment of cyclin
D1, leading to the progression of hyperplasia to endome-
trial endometriod carcinoma [7-9]. Many association
studies have focused their attention to the functionally
significant 870 G>A polymorphism in cyclin D1 which
creates two different splice variant transcripts [10]. The
normal transcript encodes exon 5 which is essential for
ubiquitin-mediated proteolysis whereas the other tran-
script lacks the destruction box in exon 5 and increases the
half life of cyclin D1 [10]. The A allele of the 870 G>A pol-
ymorphism in cyclin D1 encodes the alternate transcript
and increased levels of cyclin D1 are also evident in the
heterozygous state [10,11].
Previous studies have reported inconsistent findings for
the cyclin D1 polymorphism and a number of different
cancers. With respect to endometrial cancer, there has
been one published report on the association between the
cyclin D1 870 G>A polymorphism and endometrial can-
cer risk in Korean women [12]. Kang et al. (2005) [12]
reported that endometrial cancer patients with the AA
genotype had an increased risk of disease compared to car-
riers of the GG genotype and the combination of the GG
and GA genotypes, suggestive of a recessive model for the
A allele.
Endometrial cancer is the most common gynaecological
malignancy in Western countries and it is important to
determine the genetic variants associated with disease
since the genetic basis is poorly understood. Estrogen and
its metabolites have been associated with an increased risk
of developing endometrial cancer due to their ability to
cause DNA damaging events [13], therefore cell cycle con-
trol is integral for the recognition, repair and/or elimina-
tion of DNA damage to prevent the initiation of cancer.
The focus of this study was to examine the 870 G>A poly-
morphism in cyclin D1 and its association with endome-
trial cancer risk in Caucasians including 191 endometrial
cancer cases and 291 controls.
Methods
Study Population
This study initially consisted of 213 consecutively
recruited women with histologically confirmed endome-
trial cancer who presented for treatment at the Hunter
Centre for Gynaecological Cancer, John Hunter Hospital,
Newcastle, New South Wales, Australia between the years
1992 and 2005. Women that had additionally been diag-
nosed with breast cancer were excluded from this study.
The final analysis included 191 endometrial cancer
patients. Data on reproductive and environmental risk
factors including ethnicity, body mass index (BMI), diabe-
tes, high blood pressure (HBP), age of diagnosis of
endometrial cancer, age of menarche, age of menopause,
other personal cancer history, family history of cancer
(defined as cancer in the index patient plus one or more
first or second degree relatives diagnosed with cancer),
parity, breastfeeding, oral contraceptive use, chemother-
apy, radiotherapy, hormone therapy (HT), smoking and
alcohol use was collected using self reported question-
naires. Information regarding recurrence, stage, grade and
histology of endometrial cancer was collected from the
medical records.
The control population consisted of 291 women who
were recruited between the years 2004 and 2005 for the
Hunter Community Study. This study aims to identify
genetic and environmental factors associated with ageing
in a cohort of individuals obtained from the Hunter
region, Newcastle, New South Wales, Australia. Any con-
trol that had a prior diagnosis of either breast or endome-
trial cancer was excluded from the study. Controls were
matched to cases by sex and age.
All participants provided informed written consent prior
to participation in this study. Ethics approval was
obtained from the Human Research Ethics Committee,
University of Newcastle and the Hunter Area Research
Ethics Committee, Hunter New England Health Service,
Newcastle, New South Wales, Australia.
DNA Isolation
Genomic DNA was extracted from 10 ml EDTA blood as
previously described [14].
Molecular Analysis
Genotyping of the cyclin D1 870 G>A polymorphism
(rs603965) was performed on an ABI PRISM® 7500 Real-
Time PCR System (PE Applied Biosystems, Foster City,
CA), using primers and probes from Assay-by-Demand
(Applied Biosystems) (assay ID: C_744725_1). The assay
was performed under universal conditions previously
described [15]. The genotyping results were confirmed by
a second laboratory research assistant and 5% of the sam-
ples were re-genotyped with 100% concordance. Any
sample where a genotype could not be accurately assessed
was re-genotyped. If it failed a second time, it was dis-
carded from the analysis. The overall call rates were in the
range from 99.7–100%.BMC Cancer 2008, 8:272 http://www.biomedcentral.com/1471-2407/8/272
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Statistical Analysis
Power calculations were performed using Quanto (Ver-
sion 1.2.3, May 2007, http://hydra.usc.edu/GxE. The
number of cases and controls were chosen to detect a 2-
fold increased risk, assuming a dominant genetic model,
minor allele frequency of 6.5%, p = 0.05, 80% power and
1.52 control/case ratio. For each polymorphism, Hardy-
Weinberg Equilibrium (HWE) was calculated in the con-
trol groups to check for compliance using the Institute for
Human Genetics, statistics website, http://ihg2.helm
holtz-muenchen.de/ihg/snps.html (Munich, Germany).
To determine differences in genotype frequencies and
environmental and reproductive risk factors between the
cases and controls, chi-squared (χ2) statistics, odds ratios
(ORs) and 95% confidence intervals (CI) were calculated
using unconditional logistic regression. Multivariate
unconditional logistic regression was performed to deter-
mine if any risk factors altered the significance of the gen-
otype frequency results. The risk factors taken into
account were: BMI (<25 and ≥ 25 kg/m2) diabetes (yes/
no), HBP (yes/no), HT (yes/no), personal history of can-
cer (yes/no), smoking (ever/never) and alcohol consump-
tion (ever/never). Other risk factors such as age of
menopause were not included in the analysis since this
information was not available for the controls.
The genotype frequencies of the cyclin D1 870 G>A poly-
morphism was compared in the case group stratified for
the following environmental and reproductive risk fac-
tors; BMI (<25 versus >= 25), age of menarche (<12 v >=
12), age of menopause (<50 versus >= 50), parity (yes/
no), oral contraceptive use (ever/never), HBP (yes/no),
diabetes (yes/no), personal history of ovarian, colorectal,
and/or cervical cancer (yes/no), radiotherapy (yes/no),
chemotherapy (yes/no), hormone therapy (yes/no), fam-
ily history of uterine, breast, colorectal and/or ovarian
cancer (yes/no, defined as one first or second degree rela-
tive with cancer), smoking (ever/never), alcohol (ever/
never), stage of cancer, grade of cancer, histology and can-
cer recurrence. This analysis was performed by using chi-
squared (χ2) analysis and ORs and 95% CIs were calcu-
lated using unconditional logistic regression.
T-tests were used to determine differences in the age of
diagnosis of endometrial cancer by genotype. Kaplan
Meier survival analysis was used to plot the cumulative
survival versus the patient's age of diagnosis of endome-
trial cancer. By comparing the Kaplan-Meier survival
curves for each genotype, we tested if there were differ-
ences in the age of diagnosis of endometrial cancer by
genotype. The Wilcoxon's test was used to determine the
significance of observations from early ages of diagnosis,
log-rank test, which gives more weight to later ages and
Tarone-Ware test, which is an intermediate of the two
other tests were used to examine the homogeneity of the
survival curves. The polymorphisms that showed a statis-
tically significant difference between the genotypes and
the age of diagnosis of endometrial cancer for all three sta-
tistical tests were further examined by a multivariate Cox
regression model where a number of specific risk factors
were incorporated into the analysis.
The significance levels of all tests were set at p < 0.05 and
were two-sided. All statistical analysis was performed with
Intercooled STATA 8.2 (Stata Corp., College Station, TX,
USA), SPSS Version 15 (SPSS Inc. Chicago, IL, USA) and
GraphPad Instat version 3.06 (GraphPad Software, San
Diego, CA, USA).
Results
Cases and controls were different with respect to potential
endometrial cancer risk factors, including HBP, diabetes,
HT, alcohol consumption, personal history of any cancer,
personal history of ovarian cancer, cervical cancer and
other cancers. The characteristics of the cases and controls
are shown in table 1. The distributions of the cyclin D1
genotypes among the controls did not deviate from HWE.
The genotype frequencies were compared between the
cases and controls for the cyclin D1 870 G>A polymor-
phism, however no significant differences were observed
(table 2). However, there was a trend for increased risk of
developing endometrial cancer for women with the AA
genotype compared to those with the GG genotype (ORadj
1.692 95% CI (0.939–3.049), p = 0.080).
Kaplan-Meier survival analysis and T-tests were used to
evaluate the influence of the cyclin D1 870 G>A polymor-
phism on the age of diagnosis of endometrial cancer. No
significant differences were observed (data not shown).
Family histories of other cancers in association with the
index endometrial cancer cases were identified in subsets
of patients. The disease associations included first and/or
second degree relatives with breast, ovarian, endometrial
and colorectal cancer. No relationships between the pres-
ence of the 870 G>A SNP and endometrial cancer in asso-
ciation with family clusterings of breast, ovarian or
endometrial cancer were observed. There was, however, a
significant association between the cyclin D1 870 G>A
polymorphism and family history of colorectal cancer
shown in table 3. Endometrial cancer patients with the
variant (AA) genotype had a higher frequency of family
members with colorectal cancer compared to those with
the GG and GA genotypes (GG versus AA; OR 2.951, 95%
CI (1.026–8.491), p = 0.045, and GG+GA versus AA; OR
2.265, 95% CI (1.048–4.894), p = 0.038).
In regards to the other environmental and reproductive
risk factors examined in the case group, the genotype fre-BMC Cancer 2008, 8:272 http://www.biomedcentral.com/1471-2407/8/272
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quencies of the cyclin D1 870 G>A polymorphism
showed no further significant results.
Discussion
It is well known that endogenous and exogenous estrogen
is implicated in endometrial cancer etiology since their
products and metabolites have the ability to cause DNA
damage. Given the importance of cell cycle control for the
maintenance of genomic integrity, it is conceivable that
polymorphisms in the genes that drive these processes
alter the efficiency of DNA repair, leading to disease initi-
ation. The current study took into account a series of envi-
ronmental and reproductive risk factors for both the cases
and controls and the results support previous epidemio-
logical data for the listed risk factors indicating that there
were no unusual environmental characteristics associated
with the study population.
This study focused on the 870 G>A polymorphism in cyc-
lin D1 and its association with endometrial cancer risk.
The 870 G>A polymorphism was not significantly associ-
ated with endometrial cancer risk. However, a trend
Table 1: Comparison of Environmental and Reproductive Risk Factors between Cases and Controls
Risk Factor Group Cases n (%) Controls n (%) OR 95% CI P value
High Blood Pressure (yes/no) yes 107 (56.0) 114 (39.2) 1.978 1.366 – 2.864 p < 0.001
no 84 (44.0) 177 (60.8)
Diabetes (yes/no) yes 44 (23.0) 31 (10.7) 2.51 1.519 – 4.148 p < 0.001
no 147 (77.0) 260 (89.3)
Hormone Therapy (yes/no) yes 47 (24.6) 40 (13.7) 2.048 1.282 – 3.273 p = 0.003
no 144 (75.4) 251 (86.3)
Alcohol consumption (ever/never) ever 92 (48.2) 228 (78.4) 0.257 0.172 – 0.382 p < 0.001
never 99 (51.8) 63 (21.6)
BMI <25 kg/m2 34 (19.1) 72 (24.7) 0.718 0.454–1.136 p = 0.157
>= 25 kg/m2 144 (80.9) 219 (75.3)
Smoking (ever/never) ever 52 (27.2) 68 (23.4) 1.227 0.807 – 1.865 p = 0.338
never 139 (72.8) 223 (76.6)
Ovarian Cancer (yes/no) yes 7 (3.7) 1 (0.3) 11.033 1.346 – 90.403 p = 0.025
no 184 (96.3) 290 (99.7)
Cervical Cancer (yes/no) yes 8 (4.2) 2 (0.7) 6.317 1.327 – 30.077 p = 0.021
no 183 (95.8) 289 (99.3)
History of Ovarian or Cervical Cancer (yes/no) yes 15 (7.9) 3 (1.0) 8.182 2.335 – 28.663 p = 0.001
no 176 (92.1) 288 (99.0)
Personal History of Any Cancer (yes/no) yes 51 (26.7) 28 (9.6) 3.422 2.066 – 5.667 p < 0.001
no 140 (73.3) 263 (90.4)
History of Skin Cancer (yes/no) yes 20 (10.5) 19 (6.5) 1.674 0.869 – 3.228 p = 0.124
no 171 (89.5) 272 (93.5)
History of Bowel Cancer (yes/no) yes 10 (5.2) 8 (2.7) 1.954 0.757 – 5.045 p = 0.166
no 181 (94.8) 283 (97.3)
Note: BMI not known for 13 cases.
Table 2: Association of Cyclin D1 870 G>A (rs603965) Polymorphism with Endometrial Cancer Risk
Genotype Cases n (%) Controls n (%) χ2 OR (95% CI) and p value
GG 49 (25.7) 93 (32.1) p = 0.161 1.00 (reference)
1.262 (0.771–2.066)adj# p = 0.355
1.256 (0.815–1.938) p = 0.302
AA 48 (25.1) 55 (19.0) 1.692 (0.939–3.049)adj# p = 0.080
1.656 (0.989–2.784) p = 0.057
GA+AA 142 (74.3) 197 (67.9) p = 0.131† 1.383 (0.869–2.201)adj# p = 0.172
1.368 (0.910–2.057) p = 0.132
GG+GA 143 (74.9) 235 (81.0) p = 0.107‡ 1.458 (0.889–2.393)adj# p = 0.135
1.434 (0.924–2.226) p = 0.108
Note: Minor Allele Frequency (MAF) 0.317.
# ORadj: Adjusted for BMI, HBP, diabetes, HT, personal history of cancer, smoking and alcohol use.
† p value: Wild type genotype (GG) compared to combination of heterozygous and homozygous variant genotypes (GA+AA).
‡ p value: Homozygous variant genotype (AA) compared to combination of wild type and heterozygous genotypes (GG+GA).BMC Cancer 2008, 8:272 http://www.biomedcentral.com/1471-2407/8/272
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towards the AA genotype imparting an increased risk of
endometrial cancer compared to the GG genotype was
observed. These results support the study of Kang et al.
(2005) [12] who found a significant association between
the AA genotype and an increased risk in endometrial can-
cer development in Korean women (GG+GA versus AA,
ORadj 2.63 (1.04–6.66), p = 0.041) and suggests that this
polymorphism is acting as a disease modifier. Even
though we did not observe a statistically significant result,
the underlying biological plausibility remains consistent
between the two studies. The most likely explanation for
the difference in the significance of the results between the
current study and that of Kang et al. (2005) [12] is the
influence of different environmental factors affecting dis-
ease risk. A number of studies have shown that overex-
pression of cyclin D1 is associated with endometrial
cancer and that it is an early event in tumourigenesis
[3,4,6-9]. One report showed that 50% (7/14) of endome-
trial carcinomas had cyclin D1 overexpression and that
there was no immunopositive difference between these
carcinomas and simple hyperplasia which is a precursor
for endometrial cancer development [3].
From the study participants two main familial associa-
tions were observed, one with colorectal cancer (36
endometrial cancer patients (18.8%) with family history
of colorectal cancer) and the other with breast cancer (44
endometrial cancer patients (23.0%) with family history
of breast cancer). Interestingly, analysing family history of
colorectal cancer in patients with endometrial cancer and
the cyclin D1 870 G>A polymorphism showed that
endometrial cancer patients with the AA genotype had a
higher frequency of family members with colorectal can-
cer compared to endometrial cancer patients with the GG
or GA genotype combinations.
The association between endometrial cancer and colorec-
tal cancer is well recognised in Lynch Syndrome (or
HNPCC); however, endometrial cancer associations with
other malignancies are less well defined and there is little
written in the literature about breast/endometrial cancer
familial clustering. No association was observed between
the cyclin D1 G870A SNP and endometrial/breast cancer
families whereas an association was observed between
this polymorphism and the increased likelihood of color-
ectal cancer in other family members.
There have been a number of studies that have focused on
the cyclin D1 870 G>A polymorphism and colorectal can-
cer development however these reports are somewhat
conflicting [16-18]. Some studies have reported an associ-
ation between the cyclin D1 870 G>A polymorphism and
the age of diagnosis of colorectal disease in HNPCC [19-
21]. Endometrial cancer is the most common cancer in
women with HNPCC and the second most common can-
cer overall in this syndrome [22], therefore the association
of the cyclin D1 870 G>A polymorphism and a family his-
tory of colorectal cancer is intriguing and suggests that this
polymorphism may be related to the increased risk of
endometrial cancer in HNPCC.
This study has a number of strengths since it was a popu-
lation-based case-control investigation that had a rela-
tively large sample size to detect an association and
detailed information of specific risk factors. However,
these results must be confirmed in a larger population and
more studies should be conducted on the association
between the cyclin D1 870 G>A polymorphism and
endometrial cancer risk. Additionally, the relationship
between the cyclin D1 870 G>A polymorphism and
HNPCC, specifically hMSH2 mutation carriers, should
also be confirmed in further studies.
In conclusion, we have shown that the 870 G>A polymor-
phism in cyclin D1 may be associated with endometrial
cancer risk and provided support for an association with
colorectal cancer risk.
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